查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1538521

新抗原癌症疫苗市场报告：2030 年趋势、预测与竞争分析

Neoantigen Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

新抗原癌症疫苗的趋势和预测

预计到 2030 年，全球新抗原癌症疫苗市场预计将达到 9,030 万美元，2024 年至 2030 年复合年增长率为 22.4%。这个市场的主要驱动力是越来越多地使用个人化医疗对患者进行个人化治疗、全球癌症发病率上升以及免疫疗法和个人化医疗的持续进步。全球新抗原癌症疫苗市场前景广阔，黑色素瘤、脑肿瘤、胃肠道和肺部市场都有机会。

新抗原癌症疫苗细分市场

该研究包括按产品、给药途径、细胞、应用和区域对全球新抗原癌症疫苗的预测。

新抗原癌症疫苗市场洞察

Lucintel 预测，个人化新抗原将在预测期内实现高速成长。

在该市场中，肺臟预计在预测期内将呈现最高成长。

预计北美在预测期内将出现最高成长。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球新抗原癌症疫苗市场预计将达到 9,030 万美元。

Q2.市场成长预测是多少：

A2. 2024年至2030年，全球新抗原癌症疫苗市场预计将以22.4%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 这个市场的主要驱动力是越来越多地使用个人化医疗来对患者进行个人化治疗、全球癌症发病率上升以及免疫疗法和个人化医疗的不断进步。

Q4.市场的主要细分市场是：

A4. 新抗原癌症疫苗市场前景广阔，在黑色素瘤、脑瘤、胃肠道和肺部市场都有机会。

Q5.市场的主要企业是：

A5. 生产新抗原癌症疫苗的主要企业如下：

  • Avidea Technologies
  • Agenus
  • Roche
  • Nouscom
  • Genocea Biosciences
  • Gritstone Oncology
  • Gilead Sciences
  • BioNTech
  • ISA Pharmaceutical
  • Vaccibody

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测个人化新抗原将在预测期内呈现高速成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 预计北美地区在预测期内将出现最高成长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球新抗原癌症疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球新抗原癌症疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 全球新抗原癌症疫苗市场（按产品）
    • 个人化新抗原疫苗
    • 现成的新抗原疫苗
  • 按给药途径的全球新抗原癌症疫苗市场
    • 静脉
    • 肌肉注射
    • 经皮的
    • 其他的
  • 全球新抗原癌症疫苗市场（按细胞）
    • 自体移植
    • 同种异体的
  • 全球新抗原癌症疫苗市场（按应用）
    • 恶性黑色素瘤
    • 脑肿瘤
    • 胃肠道
    • 肺
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球新抗原癌症疫苗市场区域分布
  • 北美新抗原癌症疫苗市场
  • 欧洲新抗原癌症疫苗市场
  • 亚太地区新抗原癌症疫苗市场
  • 其他地区新抗原癌症疫苗市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球新抗原癌症疫苗市场成长机会（按产品）
    • 按途径的全球新抗原癌症疫苗市场成长机会
    • 全球新抗原癌症疫苗市场成长机会（按细胞）
    • 全球新抗原癌症疫苗市场成长机会（按应用）
    • 全球新抗原癌症疫苗市场成长机会（按地区）
  • 全球新抗原癌症疫苗市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球新抗原癌症疫苗市场产能
    • 全球新抗原癌症疫苗市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • Avidea Technologies
  • Agenus
  • Roche
  • Nouscom
  • Genocea Biosciences
  • Gritstone Oncology
  • Gilead Sciences
  • BioNTech
  • ISA Pharmaceutical
  • Vaccibody
简介目录

Neoantigen Cancer Vaccine Trends and Forecast

The future of the global neoantigen cancer vaccine market looks promising with opportunities in the melanoma, brain cancer, gastrointestinal, and lung markets. The global neoantigen cancer vaccine market is expected to reach an estimated $90.3 million by 2030 with a CAGR of 22.4% from 2024 to 2030. The major drivers for this market are growing use of personalized medicine for customized patient care, rising incidence of cancer globally, and ongoing advancements in immunotherapy and personalized medicine.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Neoantigen Cancer Vaccine by Segment

The study includes a forecast for the global neoantigen cancer vaccine by product, route of administration, cell, application, and region.

Neoantigen Cancer Vaccine Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Personalized Neo-Antigen Vaccine
  • Off-The Shell Neoantigen Vaccine

Neoantigen Cancer Vaccine Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Intravenous
  • Intramuscular
  • Transdermal
  • Others

Neoantigen Cancer Vaccine Market by Cell [Shipment Analysis by Value from 2018 to 2030]:

  • Autologous
  • Allogenic

Neoantigen Cancer Vaccine Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Melanoma
  • Brain Cancer
  • Gastrointestinal
  • Lung
  • Others

Neoantigen Cancer Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Neoantigen Cancer Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neoantigen cancer vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neoantigen cancer vaccine companies profiled in this report include-

  • Avidea Technologies
  • Agenus
  • Roche
  • Nouscom
  • Genocea Biosciences
  • Gritstone Oncology
  • Gilead Sciences
  • BioNTech
  • ISA Pharmaceutical
  • Vaccibody

Neoantigen Cancer Vaccine Market Insights

Lucintel forecasts that personalized neo-antigen is expected to witness higher growth over the forecast period.

Within this market, lung is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Neoantigen Cancer Vaccine Market

Market Size Estimates: Neoantigen cancer vaccine market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neoantigen cancer vaccine market size by various segments, such as by product, route of administration, cell, application, and region in terms of value ($M).

Regional Analysis: Neoantigen cancer vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, route of administrations, cells, applications, and regions for the neoantigen cancer vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neoantigen cancer vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the neoantigen cancer vaccine market size?

Answer: The global neoantigen cancer vaccine market is expected to reach an estimated $90.3 million by 2030.

Q2. What is the growth forecast for neoantigen cancer vaccine market?

Answer: The global neoantigen cancer vaccine market is expected to grow with a CAGR of 22.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the neoantigen cancer vaccine market?

Answer: The major drivers for this market are growing use of personalized medicine for customized patient care, rising incidence of cancer globally, and ongoing advancements in immunotherapy and personalized medicine.

Q4. What are the major segments for neoantigen cancer vaccine market?

Answer: The future of the neoantigen cancer vaccine market looks promising with opportunities in the melanoma, brain cancer, gastrointestinal, and lung markets.

Q5. Who are the key neoantigen cancer vaccine market companies?

Answer: Some of the key neoantigen cancer vaccine companies are as follows:

  • Avidea Technologies
  • Agenus
  • Roche
  • Nouscom
  • Genocea Biosciences
  • Gritstone Oncology
  • Gilead Sciences
  • BioNTech
  • ISA Pharmaceutical
  • Vaccibody

Q6. Which neoantigen cancer vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that personalized neo-antigen is expected to witness higher growth over the forecast period.

Q7. In neoantigen cancer vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the neoantigen cancer vaccine market by product (personalized neo-antigen vaccine and off-the shell neoantigen vaccine), route of administration (intravenous, intramuscular, transdermal, and others), cell (autologous and allogenic), application (melanoma, brain cancer, gastrointestinal, lung, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neoantigen Cancer Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Neoantigen Cancer Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Neoantigen Cancer Vaccine Market by Product
    • 3.3.1: Personalized Neo-Antigen Vaccine
    • 3.3.2: Off-The Shell Neoantigen Vaccine
  • 3.4: Global Neoantigen Cancer Vaccine Market by Route of Administration
    • 3.4.1: Intravenous
    • 3.4.2: Intramuscular
    • 3.4.3: Transdermal
    • 3.4.4: Others
  • 3.5: Global Neoantigen Cancer Vaccine Market by Cell
    • 3.5.1: Autologous
    • 3.5.2: Allogenic
  • 3.6: Global Neoantigen Cancer Vaccine Market by Application
    • 3.6.1: Melanoma
    • 3.6.2: Brain cancer
    • 3.6.3: Gastrointestinal
    • 3.6.4: Lung
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Neoantigen Cancer Vaccine Market by Region
  • 4.2: North American Neoantigen Cancer Vaccine Market
    • 4.2.1: North American Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
    • 4.2.2: North American Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
  • 4.3: European Neoantigen Cancer Vaccine Market
    • 4.3.1: European Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
    • 4.3.2: European Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
  • 4.4: APAC Neoantigen Cancer Vaccine Market
    • 4.4.1: APAC Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
    • 4.4.2: APAC Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others
  • 4.5: ROW Neoantigen Cancer Vaccine Market
    • 4.5.1: ROW Neoantigen Cancer Vaccine Market by Product: Personalized Neo-Antigen Vaccine and Off-The Shell Neoantigen Vaccine
    • 4.5.2: ROW Neoantigen Cancer Vaccine Market by Application: Melanoma, Brain cancer, Gastrointestinal, Lung, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Product
    • 6.1.2: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Cell
    • 6.1.4: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Application
    • 6.1.5: Growth Opportunities for the Global Neoantigen Cancer Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Neoantigen Cancer Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Neoantigen Cancer Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neoantigen Cancer Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Avidea Technologies
  • 7.2: Agenus
  • 7.3: Roche
  • 7.4: Nouscom
  • 7.5: Genocea Biosciences
  • 7.6: Gritstone Oncology
  • 7.7: Gilead Sciences
  • 7.8: BioNTech
  • 7.9: ISA Pharmaceutical
  • 7.10: Vaccibody